Payment overview · 2025
General Payments
$2,243.80
125 reported records · 17 companies
Healthcare provider profile · identity verified
Rashad Ansari, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Rheumatology · VISTA, CA · NPI 1063594372
Verified facts
What the public records show
CMS Open Payments records show Rashad Ansari, MD received $2,243.80 in general payments during 2025 across 125 reported records.
ABBVIE INC. accounted for 23.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 26 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Actemra, Enbrel, Orencia, Otezla, Rinvoq, Xeljanz.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported RINVOQ as an associated drug or biological on 279238 records involving 34343 distinct recipient NPIs. Public Medicare Part D data also shows 47 claims for Rinvoq by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENBREL as an associated drug or biological on 9330 records involving 2094 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Enbrel by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OTEZLA as an associated drug or biological on 177267 records involving 48600 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Otezla by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 105 claims for Prolia by this doctor in 2024.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ORENCIA as an associated drug or biological on 10404 records involving 2463 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Orencia by this doctor in 2024.
Genentech USA, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Actemra as an associated drug or biological on 2116 records involving 1314 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Actemra by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SIMPONI ARIA as an associated drug or biological on 28612 records involving 8458 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Simponi Aria by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XELJANZ as an associated drug or biological on 32588 records involving 8614 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xeljanz by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $529.12 | 23.6% | 24 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $401.39 | 17.9% | 42 | 2025 |
| UCB, Inc. | Unresolved — no canonical attribution shown | $290.17 | 12.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $280.29 | 12.5% | 17 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $162.17 | 7.2% | 7 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $117.70 | 5.2% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $75.83 | 3.4% | 4 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $72.30 | 3.2% | 3 | 2025 |
| Sandoz Inc. | Unresolved — no canonical attribution shown | $62.07 | 2.8% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $53.31 | 2.4% | 2 | 2025 |
| Genentech USA, Inc. | Unresolved — no canonical attribution shown | $52.17 | 2.3% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $38.92 | 1.7% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $30.43 | 1.4% | 1 | 2025 |
| KYOWA KIRIN, INC. | Unresolved — no canonical attribution shown | $26.85 | 1.2% | 1 | 2025 |
| Aurinia Pharma U.S., Inc. | Unresolved — no canonical attribution shown | $18.71 | 0.8% | 1 | 2025 |
| Celltrion USA Inc. | Unresolved — no canonical attribution shown | $16.49 | 0.7% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $15.88 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,243.80 | 125 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TREMFYA Normalized: tremfya |
Drug | Janssen Biotech, Inc. | $401.39 | 42 | 2025 |
Source payment records
|
|||||
| RINVOQ Normalized: rinvoq |
Biological | ABBVIE INC. | $353.53 | 18 | 2025 |
Source payment records
|
|||||
| Bimzelx Normalized: bimzelx |
Biological | UCB, Inc. | $290.17 | 9 | 2025 |
Source payment records
|
|||||
| SKYRIZI Normalized: skyrizi |
Biological | ABBVIE INC. | $175.59 | 6 | 2025 |
Source payment records
|
|||||
| SAPHNELO Normalized: saphnelo |
Biological | AstraZeneca Pharmaceuticals LP | $145.15 | 6 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $134.65 | 9 | 2025 |
Source payment records
|
|||||
| COSENTYX Normalized: cosentyx |
Drug | Novartis Pharmaceuticals Corporation | $97.95 | 4 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $92.78 | 5 | 2025 |
Source payment records
|
|||||
| ENBREL Normalized: enbrel |
Biological | Amgen Inc. | $84.05 | 6 | 2025 |
Source payment records
|
|||||
| TALTZ Normalized: taltz |
Drug | Lilly USA, LLC | $75.83 | 4 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $75.83 | 4 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $72.30 | 3 | 2025 |
Source payment records
|
|||||
| HYRIMOZ Normalized: hyrimoz |
Biological | Sandoz Inc. | $62.07 | 3 | 2025 |
Source payment records
|
|||||
| OLUMIANT Normalized: olumiant |
Drug | Lilly USA, LLC | $58.92 | 3 | 2025 |
Source payment records
|
|||||
| XELJANZ Normalized: xeljanz |
Drug | PFIZER INC. | $53.31 | 2 | 2025 |
Source payment records
|
|||||
| TAVNEOS Normalized: tavneos |
Drug | Amgen Inc. | $52.86 | 3 | 2025 |
Source payment records
|
|||||
| OPSUMIT Normalized: opsumit |
Drug | Actelion Pharmaceuticals US, Inc. | $52.68 | 2 | 2025 |
Source payment records
|
|||||
| Actemra Normalized: actemra |
Biological | Genentech USA, Inc. | $52.17 | 2 | 2025 |
Source payment records
|
|||||
| BENLYSTA Normalized: benlysta |
Biological | GlaxoSmithKline, LLC. | $38.92 | 2 | 2025 |
Source payment records
|
|||||
| ORENCIA Normalized: orencia |
Biological | E.R. Squibb & Sons, L.L.C. | $30.43 | 1 | 2025 |
Source payment records
|
|||||
| CRYSVITA Normalized: crysvita |
Drug | KYOWA KIRIN, INC. | $26.85 | 1 | 2025 |
Source payment records
|
|||||
| ILARIS Normalized: ilaris |
Drug | Novartis Pharmaceuticals Corporation | $19.75 | 1 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $19.62 | 1 | 2025 |
Source payment records
|
|||||
| LUPKYNIS Normalized: lupkynis |
Drug | Aurinia Pharma U.S., Inc. | $18.71 | 1 | 2025 |
Source payment records
|
|||||
| VEGZELMA Normalized: vegzelma |
Biological | Celltrion USA Inc. | $16.49 | 1 | 2025 |
Source payment records
|
|||||
| TONMYA Normalized: tonmya |
Drug | Tonix Medicines, Inc. | $15.88 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| Actemra actemra |
2025 | Actemra | 2024 | 35 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ENBREL enbrel |
2025 | Enbrel | 2024 | 25 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| ORENCIA orencia |
2025 | Orencia | 2024 | 106 | exact normalized | Medicare Part D |
| OTEZLA otezla |
2025 | Otezla | 2024 | 37 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| RINVOQ rinvoq |
2025 | Rinvoq | 2024 | 47 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| XELJANZ xeljanz |
2025 | Xeljanz | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | RINVOQ open payments reported associated product |
CMS Open Payments — General Payments 279238 supporting records · 34343 recipient NPIs · example record 1201352600 |
Rinvoq · 2024 Exact normalized brand match · 1 Part D row |
47 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | ENBREL open payments reported associated product |
CMS Open Payments — General Payments 9330 supporting records · 2094 recipient NPIs · example record 1226877474 |
Enbrel · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | OTEZLA open payments reported associated product |
CMS Open Payments — General Payments 177267 supporting records · 48600 recipient NPIs · example record 1226871616 |
Otezla · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
105 | 69 |
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ORENCIA open payments reported associated product |
CMS Open Payments — General Payments 10404 supporting records · 2463 recipient NPIs · example record 1184378623 |
Orencia · 2024 Exact normalized brand match · 1 Part D row |
106 | 11 |
| Genentech USA, Inc. Exact reporting entity; no affiliate inference |
2025 | Actemra open payments reported associated product |
CMS Open Payments — General Payments 2116 supporting records · 1314 recipient NPIs · example record 1211488494 |
Actemra · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | SIMPONI ARIA open payments reported associated product |
CMS Open Payments — General Payments 28612 supporting records · 8458 recipient NPIs · example record 1174257377 |
Simponi Aria · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | XELJANZ open payments reported associated product |
CMS Open Payments — General Payments 32588 supporting records · 8614 recipient NPIs · example record 1228794176 |
Xeljanz · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Prednisone | Prednisone | 471 | 131 |
| Celecoxib | Celecoxib | 362 | 107 |
| Methotrexate | Methotrexate Sodium | 225 | 50 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 168 | 37 |
| Humira Pen | Adalimumab | 150 | 13 |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 140 | 31 |
| Meloxicam | Meloxicam | 136 | 46 |
| Xeljanz Xr | Tofacitinib Citrate | 115 | 11 |
| Duloxetine Hcl | Duloxetine Hcl | 107 | 26 |
| Gabapentin | Gabapentin | 106 | 25 |
| Orencia | Abatacept/Maltose | 106 | 11 |
| Prolia | Denosumab | 105 | 69 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 102 | 16 |
| Pregabalin | Pregabalin | 85 | 18 |
| Allopurinol | Allopurinol | 78 | 18 |
| Enbrel Sureclick | Etanercept | 77 | suppressed |
| Orencia Clickject | Abatacept | 76 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 67 | 19 |
| Omeprazole | Omeprazole | 52 | 16 |
| Alendronate Sodium | Alendronate Sodium | 48 | 18 |
| Fentanyl | Fentanyl | 47 | suppressed |
| Rinvoq | Upadacitinib | 47 | suppressed |
| Levothyroxine Sodium | Levothyroxine Sodium | 40 | suppressed |
| Leflunomide | Leflunomide | 39 | suppressed |
| Otezla | Apremilast | 37 | suppressed |
| Actemra | Tocilizumab | 35 | suppressed |
| Folic Acid | Folic Acid | 35 | 14 |
| Lidocaine | Lidocaine | 34 | suppressed |
| Etodolac | Etodolac | 33 | 12 |
| Cosentyx Sensoready (2 Pens) | Secukinumab | 30 | suppressed |
| Ibuprofen | Ibuprofen | 28 | suppressed |
| Enbrel | Etanercept | 25 | suppressed |
| Febuxostat | Febuxostat | 24 | suppressed |
| Azathioprine | Azathioprine | 22 | suppressed |
| Amlodipine Besylate | Amlodipine Besylate | 19 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 19 | suppressed |
| Mycophenolate Mofetil | Mycophenolate Mofetil | 17 | suppressed |
| Simponi Aria | Golimumab | 16 | suppressed |
| Evenity (2 Syringes) | Romosozumab-Aqqg | 14 | suppressed |
| Mirtazapine | Mirtazapine | 14 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 14 | suppressed |
| Oxycontin | Oxycodone Hcl | 13 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 13 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 13 | suppressed |
| Xeljanz | Tofacitinib Citrate | 13 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 12 | suppressed |
| Clonazepam | Clonazepam | 12 | suppressed |
| Losartan Potassium | Losartan Potassium | 12 | suppressed |
| Diazepam | Diazepam | 11 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 11 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,243.80 · 125 records | ABBVIE INC. | Actemra, BENLYSTA, Bimzelx, COSENTYX, CRYSVITA, ENBREL, EVENITY, HYRIMOZ, ILARIS, LUPKYNIS, OLUMIANT, OPSUMIT, OPSYNVI, ORENCIA, OTEZLA, RINVOQ, SAPHNELO, SKYRIZI, TALTZ, TAVNEOS, TONMYA, TREMFYA, UPTRAVI, VEGZELMA, XELJANZ, ZEPBOUND | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Actemra play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error